Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Travere Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Travere Therapeutics, Inc.

TVTX

Travere Therapeutics, Inc.

About Travere Therapeutics, Inc.

Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its core products include FILSPARI (sparsentan) for IgA nephropathy and FSGS, and pegtibatinase for homocystinuria. The company leverages clinical expertise, innovative pipeline development, and strategic licensing to address significant unmet medical needs in niche markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Travere Therapeutics, Inc.

1
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 55.6% Revenue Growth to $127.2 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 110.5% Revenue Growth to $490.7 Million in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 162% Revenue Growth to $164.9 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 111.5% Revenue Growth to $114.4 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Travere Therapeutics, Inc. Travere Therapeutics Reports $81.7 Million Revenue in Q1 2025, Significant Loss Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 60.5% Revenue Growth to $233.2 Million in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Travere Therapeutics, Inc. Travere Therapeutics Reports 82% Increase in Net Product Sales, Net Loss Narrows in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments